

Supplementary Online Content

O'Fee K, Deych E, Ciani O, Brown DL. Assessment of nonfatal myocardial infarction as a surrogate for all-cause and cardiovascular mortality in treatment or prevention of coronary artery disease: a meta-analysis of randomized clinical trials. *JAMA Intern Med*. Published online October 25, 2021. doi:10.1001/jamainternmed.2021.5726

eFigure 1. Funnel Plots for Nonfatal Myocardial Infarction and All-cause Mortality

eFigure 2. Treatment Effect of Myocardial Infarction (MI) and All-cause Mortality by Study Type

eFigure 3. Subgroup Analysis by Years of Follow-up for the Association Between the Logarithm of the Odds Ratios (OR) for Surrogate End Point of Myocardial Infarction (MI) and True Endpoint of All-cause Mortality

eFigure 4. Subgroup Analysis by Type of Control Arm for the Association Between the Logarithm of the Odds Ratios (OR) for Surrogate End Point of Myocardial Infarction (MI) and True End Point of All-cause Mortality

eAppendix. Search Strategy

eTable 1. Trial Characteristics

eTable 2. Assessment of Risk of Bias


eTable 3. Trial Abbreviations, Names, and Date of Publication

eReferences


This supplementary material has been provided by the authors to give readers additional information about their work.

Figure 1. Funnel plots for nonfatal myocardial infarction and all-cause mortality.

1A. Nonfatal myocardial infarction




1B. All-cause mortality




eFigure 2. Treatment effect of myocardial infarction (MI) and all-cause mortality by study type


2A. Revascularization




2B. Primary prevention




2C. Mixed primary/secondary prevention




2C. (continued)



2D. Secondary prevention




2D. (continued)




eFigure 3. Subgroup analysis by years of follow-up for the association between the logarithm of the odds ratios (OR) for surrogate endpoint of myocardial infarction (MI) and true endpoint of all-cause mortality


3A. 2-3.9 years



3B. 4-5.9 years




3C. ≥ 6 years




eFigure 4. Subgroup analysis by type of control arm for the association between the logarithm of the odds ratios (OR) for surrogate endpoint of myocardial infarction (MI) and true endpoint of all-cause mortality

4A. Placebo



4B. Active control



eAppendix. Search Strategy

Pubmed

("cardiovascular events"[All Fields] OR "cardiovascular event"[All Fields]) OR (("myocardial infarction"[All Fields] OR "myocardial infarction"[All Fields]) AND (("death"[MeSH Terms] OR "death"[All Fields]) OR ("death"[MeSH Terms] OR "death"[All Fields] OR "deaths"[All Fields]) OR ("mortality"[Subheading] OR "mortality"[All Fields] OR "mortality"[MeSH Terms]) OR ("mortality"[MeSH Terms] OR "mortality"[All Fields] OR "mortalities"[All Fields]) OR fatal[All Fields] OR fatalities[All Fields])) AND ("N Engl J Med"[Journal] OR "Lancet"[Journal] OR "JAMA"[Journal]) AND (Randomized Controlled Trial[ptyp] AND ("1945/01/01"[PDAT] : "2020/12/31"[PDAT])) AND (Randomized Controlled Trial[ptyp] AND ("1945/01/01"[PDAT] : "2020/12/31"[PDAT]))

eTable 1. Trial Characteristics

Trial name, publication date	Year of First Patient Enrollment	Investigational arm	Control arm	MI definition	Investigational arm, N	Control arm, N	Median follow-up, years
Revascularization trials (N=17)							
RITA-1, 1998	1988	Percutaneous transluminal coronary angioplasty (PTCA)	Coronary artery bypass grafting (CABG)	WHO definition ¹	510	501	6.5
RITA-2, 1997	1992	PTCA	Optimal medical therapy (OMT)	WHO definition	504	514	2.7
RITA-3, 2005	1997	Early invasive strategy	Conservative strategy	WHO definition	895	915	5
COURAGE, 2007	1999	Percutaneous coronary intervention (PCI) and OMT	OMT	COURAGE definition ²	1149	1138	4.6
OAT, 2006	2000	PCI and OMT	OMT	OAT definition ³	1082	1084	3
BARI 2D, 2009	2001	Revascularization and OMT	OMT	BARI 2D trial definition ⁴	1176	1192	5.3
ROOBY-FS, 2017	2002	Off pump CABG	On pump CABG	Universal definition of myocardial infarction (UDMI), 2007 ⁵	1104	1099	5
FREEDOM, 2012	2005	PCI	CABG	FREEDOM Trial definition ⁶	953	947	3.8
CORONARY, 2016	2006	Off pump CABG	On pump CABG	ACC definition clinical outcomes for patients with ACS ⁷	2375	2377	4.8
SORT OUT III, 2014	2006	Zotarolimus-eluting stent	Sirolimus eluting stent	ICD-10 Diagnosis Code I21.9	1162	1170	5

EXAMINATION, 2016	2008	Everolimus-eluting stent	Bare-metal stent	WHO extended definition ⁸	751	747	5
NORSTENT, 2016	2008	Drug-eluting stent	Bare-metal stent	Third UDMI, 2012 ⁹	4504	4509	4.9
EXCEL, 2019	2010	PCI	CABG	EXCEL trial definition ¹⁰	948	957	5
DANAMI 3-DEFER, 2016	2011	Deferred PCI	Standard PCI	Third UDMI, 2012	603	612	3.5
ISCHEMIA, 2020	2012	Early invasive angiography and OMT	OMT	ISCHEMIA trial definition (modified Third UDMI) ¹¹	2588	2591	3.2
COMPLETE, 2019	2013	Complete revascularization including non-culprit lesion(s)	Revascularization of culprit lesion (s)	Third UDMI, 2012	2016	2025	3
REGROUP, 2019	2014	Endoscopic vein-graft harvesting CABG	Open vein-graft harvesting CABG	Third UDMI	576	574	2.8

Primary prevention trials (N= 24)

Hjermann et al, 1981	1972	Smoking cessation and dietary consultation	Standard of care	WHO definition	604	628	5
LRC-CPPT, 1984	1973	Cholestyramine	Placebo	WHO definition	1906	1900	7.4
Kornitzer et al, 1983	1974	Smoking cessation, weight loss, exercise, and dietary consultation	Standard of care	WHO definition	8525	9855	5.5
Rose et al, 1983	1974	Smoking cessation, weight loss, exercise, and dietary consultation	Standard of care	WHO definition	9734	7617	5.5

PHS, 1989	1981	Aspirin	Placebo	WHO definition	11037	11034	5
SAPAT, 1992	1985	Aspirin and sotalol	Placebo and sotalol	WHO definition	1009	1026	4.2
AFCAPS/TexCAPS, 1998	1990	Lovastatin	Placebo	WHO definition	3304	3301	5.2
WHS, 2005	1992	Aspirin	Placebo	WHO definition	19934	19942	10.1
WHS, 2005	1992	Vitamin E	Placebo	WHO definition	19937	19939	10.1
ALERT, 2003	1996	Fluvastatin	Placebo	WHO definition	1050	1052	5.1
CARDS, 2004	1997	Atorvastatin	Placebo	WHO definition	1428	1410	3.9
DIAD, 2009	2000	Myocardial perfusion imaging	Standard of care	Joint ESC/ACC definition ¹²	561	562	4.8
JPPP, 2014	2005	Aspirin	Standard of care	AHA/ESC epidemiology and clinical research studies definition ¹³	7220	7244	5
ASCEND, 2018	2005	Aspirin	Placebo	Joint ESC/ACC definition	7740	7740	7.4
ASCEND, 2018	2005	Omega-3 fatty acid	Placebo	Joint ESC/ACC definition	7740	7740	7.4
HOPE-3, 2016	2007	Rosuvastatin	Placebo	Third UDMI, 2012	6361	6344	5.6
ARRIVE, 2018	2007	Aspirin	Placebo	WHO definition	6270	6276	5
CSPPT, 2015	2008	Folic acid and enalapril	Enalapril	Joint ESC/ACC definition	10348	10354	4.5
PROMISE, 2015	2010	Coronary computed tomographic angiography (CCTA)	Functional stress test	UDMI, 2007	4996	5007	2.1

SCOT-HEART, 2018	2010	CCTA	Standard of care	UDMI, 2007	2073	2073	4.8
ASPREE, 2018	2010	Aspirin	Placebo	Joint ESC/ACC definition	9525	9589	4.7
VITAL, 2019	2011	Omega-3 fatty acid	Placebo	Third UDMI, 2012	12933	12938	5.3
VITAL, 2019	2011	Vitamin D	Placebo	Third UDMI, 2012	12927	12944	5.3
THEMIS, 2019	2014	Ticagrelor and aspirin	Aspirin and placebo	Third UDMI, 2012	9619	9601	3.3
Mixed primary/secondary prevention (N= 57)							
UKPDS 33, 1998	1977	Intensive glycemic control	Standard glycemic control	WHO definition	2729	1138	10
ETDRS, 1992	1980	Aspirin	Placebo	WHO definition	1856	1855	5
SALT, 1991	1984	Aspirin	Placebo	WHO definition	676	684	2.7
STOP-Hypertension, 1991	1985	Active antihypertensive therapy	Placebo	WHO definition	812	815	4
SHEP, 1991	1985	Active antihypertensive therapy	Placebo	WHO definition	2365	2371	4.5
SOLVD, 1992	1986	Enalapril	Placebo	WHO definition	3396	3401	5
Indo-Mediterranean Diet Heart Study, 2002	1989	Dietary consultation	Standard of care	WHO definition	499	501	2
CAPPP, 1999	1991	Captopril	Beta blocker or diuretic	WHO definition	5492	5493	6.1
NORDIL, 2000	1992	Diltiazem	Beta-blocker and diuretic	WHO definition	5410	5471	4.5
ALLHAT, 2000	1994	Chlorthalidone	Doxazosin	WHO definition	15268	9067	3.3
HPS, 2002	1994	Anti-oxidant vitamins	Placebo	WHO definition	10269	10267	5
HPS, 2002	1994	Simvastatin	Placebo	WHO definition	10269	10267	5

ALLHAT-LLT, 2002	1994	Pravastatin	Standard of care	WHO definition	5170	5185	4.8
LIFE, 2002	1995	Losartan	Atenolol	WHO definition	660	666	4.7
PROSPER, 2002	1997	Pravastatin	Placebo	WHO definition	2891	2913	3.2
ESPRIT, 2006	1997	Aspirin and dipyridamole	Aspirin	WHO definition	1363	1376	3.5
PHS II, 2012	1997	Multivitamin	Placebo	WHO definition	7317	7324	11.2
4D, 2005	1998	Atorvastatin	Placebo	WHO definition	619	636	4
FIELD, 2005	1998	Fenofibrate	Placebo	WHO definition	4895	4900	5
RUTH, 2006	1998	Raloxifene	Placebo	WHO definition	5044	5057	5.6
WAFACS, 2008	1998	Vitamins B6, B9, and B12	Placebo	WHO definition	2721	2721	7.3
FeAST, 2007	1999	Phlebotomy	Standard of care	Joint ESC/ACC definition	636	641	3.5
WAVE, 2007	2000	Anti-coagulation and anti-platelet	Anti-platelet	WHO definition	1080	1081	2.9
VADT, 2015	2000	Intensive glycemic control	Standard glycemic control	ICD-9 diagnosis code 410.x	837	818	9.8
ADVANCE, 2007	2001	Perindopril-indapamide	Placebo	WHO definition	5569	5571	4.3
ADVANCE, 2008	2001	Gliclazide for intensive glycemic control	Standard glycemic control	WHO definition	5571	5569	4.3
TRANSCEND, 2008	2001	Telmisartan	Placebo	ACC definition clinical outcomes for patients with ACS	2954	2972	4.6
RECORD, 2009	2001	Rosiglitazone	Standard of care	Joint ESC/ACC definition	2220	2227	5.5

ACCORD, 2010	2001	Intensive blood pressure control	Standard blood pressure control	ACCORD definition ¹⁴	2362	2371	4.7
ACCORD, 2010	2001	Fenofibrate	Placebo	ACCORD definition	2765	2753	4.7
ACCORD, 2011	2001	Intensive glycemic control	Standard glycemic control	ACCORD definition	5128	5123	4.7
Look AHEAD, 2013	2001	Decreased caloric intake and increase physical activity	Standard of care	UDMI, 2007	2570	2575	9.6
CHARISMA, 2006	2002	Clopidogrel and Aspirin	Placebo and Aspirin	Joint ESC/ACC definition	7802	7801	2.3
NAVIGATOR, 2010	2002	Valsartan	Placebo	UDMI, 2007	4631	4675	6.5
NAVIGATOR, 2010	2002	Nateglinide	Placebo	UDMI, 2007	4645	4661	6.5
PRoFESS, 2008	2003	Aspirin and dipyridamole	Clopidogrel	WHO definition	10181	10151	2.5
ROADMAP, 2011	2004	Olmesartan	Placebo	Joint ESC/ACC definition	2232	2215	3.2
IRIS, 2016	2005	Pioglitazone	Placebo	Third UDMI, 2012	1939	1937	4.8
PERFORM, 2011	2006	Terutroban	Aspirin	UDMI, 2007	9556	9544	2.4
SAVOR-TIMI 53, 2013	2010	Saxagliptin	Placebo	UDMI, 2007	8280	8212	2.1
EMPA-REG OUTCOME, 2015	2010	Empagliflozin	Placebo	UDMI, 2007	4687	2333	3.1
SPRINT, 2015	2010	Intensive blood pressure control	Standard blood pressure control	UDMI, 2007	4678	4683	3.3
LEADER, 2016	2010	Liraglutide	Placebo	UDMI, 2007	4668	4672	3.8
SPRINT, 2016	2010	Intensive blood pressure control	Standard blood pressure control	UDMI, 2007	1317	1319	3.1
EXSCEL, 2017	2010	Exenatide	Placebo	UDMI, 2007	7356	7396	3.2
CARES, 2018	2010	Febuxostat	Allopurinol	UDMI, 2007	3098	3092	2.7
Amarenco et al, 2020	2010	Low target LDL	High target LDL	UDMI, 2007	1430	1430	3.5

PolyIran, 2019	2011	Polypill tablet	Non-pharmacologic intervention	ICD-10 diagnosis code I21	3421	3417	3
REDUCE-IT, 2019	2011	Icosapent ethyl	Placebo	UDMI, 2007	4089	4090	4.9
REWIND, 2019	2011	Dulaglutide	Placebo	UDMI, 2007	4949	4952	5.4
Nissen et al, 2018	2012	Naltrexone and bupropion	Placebo	UDMI, 2007	4455	4450	2.3
SUSTAIN-6, 2016	2013	Semaglutide	Placebo	Third UDMI, 2012	1648	1649	2.1
CARMELINA, 2019	2013	Linagliptin	Placebo	UDMI, 2007	3494	3485	2.2
DECLARE-TIMI 58, 2019	2013	Dapagliflozin	Placebo	Third UDMI, 2012	8582	8578	4.2
PIVOTAL, 2019	2013	High-dose iron administered proactively	Low-dose iron administered reactively	Third UDMI, 2012	1093	1048	2.1
LoDoCo2, 2020	2014	Colchicine	Placebo	Third UDMI, 2012	2762	2760	2.4
VOYAGER PAD, 2020	2015	Rivaroxaban and aspirin	Placebo and aspirin	Third UDMI, 2012	3286	3278	2.3

Secondary prevention (N= 46)

Coronary Drug Project, 1972	1966	Dextrothyroxine	Placebo	Diseases of the Heart and Blood Vessels, ed 6, 1964	1053	2618	3
Taylor et al, 1982	1973	Oxprenolol	Placebo	WHO definition	632	471	4
AMIS, 1980	1975	Aspirin	Placebo	WHO definition	2267	2257	3.2
EPSIM, 1982	1975	Oral anticoagulation (multiple agents)	Aspirin	WHO definition	652	651	2.4
BHAT, 1983	1978	Propranolol hydrochloride	Placebo	WHO definition	1916	1921	2.1
Smith et al, 1990	1983	Warfarin	Placebo	WHO definition	607	607	3.1

MDPIT, 1988	1983	Diltiazem	Placebo	WHO definition	1232	1234	2.1
ASPECT, 1994	1986	Anti-coagulation (multiple agents)	Placebo	WHO definition	1700	1704	3.1
SAVE, 1992	1987	Captopril	Placebo	WHO definition	1115	1116	3.5
4S, 1994	1988	Simvastatin	Placebo	WHO definition	2221	2223	5.4
CARE, 1996	1989	Pravastatin	Placebo	WHO definition	2081	2078	5
TRACE, 1995	1990	Trandolapril	Placebo	WHO definition	876	873	3.1
LIPID, 1998	1990	Pravastatin	Placebo	WHO definition	4512	4502	6.1
LIPID, 2000	1990	Pravastatin	Placebo	WHO definition	1633	1627	6
LIPID, 2002	1990	Pravastatin	Placebo	WHO definition	3914	3766	8
Rubins et al, 1999	1991	Gemfibrozil	Placebo	WHO definition	1264	1267	5.1
HERS II, 2002	1994	Estrogen and progesterone replacement	Placebo	WHO definition	1380	1383	6.8
LIPS, 2002	1996	Fluvastatin	Placebo	WHO definition	844	833	3.9
ESPRIT, 2002	1996	Estradiol valerate	Placebo	WHO definition	513	504	2
PEACE, 2004	1996	Trandolapril	Placebo	ACC definition clinical outcomes for patients with ACS	4158	4132	4.8
EUROPA, 2003	1997	Perindopril	Placebo	Joint ESC/ACC definition	6110	6108	4.2
TNT, 2005	1998	Atorvastatin 80mg daily	Atorvastatin 10mg daily	WHO definition	4995	5006	4.9
SEARCH, 2010	1998	Simvastatin 80mg daily	Simvastatin 20mg daily	WHO definition	6031	6033	6.7

SEARCH, 2010	1998	Vitamins B9 and B12	Placebo	WHO definition	6033	6031	6.7
IDEAL, 2005	1999	Atorvastatin	Simvastatin	Joint ESC/ACC definition	4439	4449	4.8
PROVE IT-TIMI 22, 2004	2000	Atorvastatin 80mg daily	Pravastatin 40mg daily	ACC definition clinical outcomes for patients with ACS	2099	2063	2
PROVE IT-TIMI 22, 2005	2000	Gatifloxacin	Placebo	ACC definition clinical outcomes for patients with ACS	2076	2086	2
PROactive, 2005	2001	Pioglitazone	Placebo	WHO definition	2605	2633	2.9
ARISE, 2008	2003	Succinobucol	Placebo	Joint ESC/ACC definition	3078	3066	2
AIM-HIGH, 2011	2005	Niacin	Placebo	WHO definition	1718	1696	3
IMPROVE-IT, 2015	2005	Ezetimibe and simvastatin	Simvastatin	ACC definition clinical outcomes for patients with ACS	9067	9077	6
HPS2-THRIVE, 2014	2007	Niacin and laropiprant	Placebo	UDMI, 2007	12838	12835	3.9
dal-OUTCOMES, 2012	2008	Dalcetrapib	Placebo	UDMI, 2007	7938	7933	2.6
STABILITY, 2014	2008	Darapladib	Placebo	UDMI, 2007	7924	7904	3.7
TECOS, 2015	2008	Sitagliptin	Placebo	ACC definition clinical outcomes for patients with ACS	7257	7266	3
SAVE, 2016	2008	CPAP	Usual care	ACC definition clinical	1346	1341	3.7

				outcomes for patients with ACS			
SIGNIFY, 2014	2009	Ivabradine	Placebo	UDMI, 2007	9550	9552	2.3
AleCardio, 2014	2010	Aleglitazar	Placebo	UDMI, 2007	3616	3610	2
ELIXA, 2015	2010	Lixisenatide	Placebo	AHA/ESC epidemiolog y and clinical research studies definition	3034	3034	2
ODYSSEY OUTCOMES, 2018	2012	Alirocumab	Placebo	Third UDMI, 2012	9462	9462	2.8
FOURIER, 2017	2013	Evolocumab	Placebo	Third UDMI, 2012	13784	13780	2.2
GLOBAL LEADERS, 2018	2013	Aspirin and ticagrelor one month, subsequently ticagrelor for 23 months	Aspirin and ticagrelor or clopidogrel for 12 months, subsequently aspirin for 12 months	Third UDMI, 2012	7980	7988	2
CIRT, 2019	2013	Methotrexate	Placebo	Third UDMI, 2012	2391	2395	2.3
ATPCI, 2020	2014	Trimetazidine	Placebo	Third UDMI, 2012	2998	3009	4
AFIRE, 2019	2015	Rivaroxaban	Rivaroxaban and aspirin	Third UDMI, 2012	1107	1108	2
BETonMACE, 2020	2015	Apabetalone	Placebo	Third UDMI, 2012	1212	1206	2.2

Abbreviations: CABG, coronary artery bypass grafting; CCTA, coronary computed tomographic angiography; MI, myocardial infarction; OMT, optimal medical therapy; PCI, percutaneous coronary intervention; PCTA, percutaneous transluminal coronary angioplasty; UDMI, universal definition of myocardial infarction; WHO, World Health Organization.

eTable 2. Assessment of Risk of Bias

Trial	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome assessment (attrition bias)	Selective Reporting (reporting bias)	Other bias
REGROUP	-	-	?	-	-	-	
AFIRE	-	-	?	-	-	-	
DECLARE-TIMI 58	-	-	-	-	-	-	
EXCEL	-	-	?	-	-	-	
THEMIS	-	-	-	-	-	-	
PolyIran	+	+	?	?	-	+	
CARMELINA	-	-	-	-	-	-	
CIRT	-	-	-	-	-	-	
COMPLETE	-	-	?	-	-	-	
VITAL, Omega-3 fatty acid	-	-	-	-	-	-	
VITAL, Vitamin D	-	-	-	-	-	-	
PIVOTAL	-	-	?	-	-	-	
REWIND	-	-	-	-	-	-	
REDUCE-IT	-	-	-	-	-	-	
CARES	-	-	-	-	-	-	
GLOBAL LEADERS	-	-	?	-	-	-	
SCOT-HEART	-	-	?	?	-	-	
ODYSSEY OUTCOMES	-	-	-	-	-	-	
ASPREE	-	-	-	-	-	-	
ARRIVE	-	-	-	-	-	-	
ASCEND, Aspirin	-	-	-	-	-	-	
ASCEND, Omega-3 Fatty Acid	-	-	-	-	-	-	
ROOBY-FS	-	-	?	-	-	-	
FOURIER	-	-	-	-	-	-	
EXSCEL	-	-	-	-	-	-	
HOPE-3	-	-	-	-	-	-	
SPRINT, 2016 EXAMINATION	-	-	?	-	-	-	
Nissen et al, 2016	-	-	-	-	-	-	
SAVE, 2016	-	-	?	-	-	-	
LEADER	-	-	-	-	-	-	
SUSTAIN-6	-	-	-	-	-	-	
CORONARY IRIS	-	-	+	-	-	-	
	-	-	-	-	-	-	

DANAMI 3-DEFER	-	-	?	-	-	-	
NORSTENT	-	-	?	-	-	-	
EMPA-REG OUTCOME	-	-	-	-	-	-	
SPRINT, 2015	-	-	?	-	-	-	
ELIXA	-	-	-	-	-	-	
CSPPT	-	-	-	-	-	-	
VADT	-	-	?	-	?	-	
TECOS	-	-	-	-	-	-	
PROMISE	-	-	?	-	-	-	
IMPROVE-IT	-	-	-	-	-	-	
STABILITY	-	-	-	-	-	-	
SORT OUT III	-	-	?	-	-	-	
AleCardio	?	?	-	-	-	-	
JPPP	-	-	?	-	-	-	
HPS2-THRIVE	-	-	-	-	-	-	
SIGNIFY	-	-	-	-	-	-	
SAVOR-TIMI 53	-	-	-	-	-	-	
Look AHEAD	-	-	?	-	-	-	
PHS II	-	?	-	-	-	-	
dal-OUTCOMES	-	-	-	-	-	-	
FREEDOM	-	-	?	?	-	-	
ROADMAP	-	-	-	-	-	-	
PERFORM	-	-	-	-	-	-	
AIM-HIGH	-	-	-	-	-	-	
ACCORD, 2011	-	-	?	-	-	-	
SEARCH, Simvastatin	-	-	-	-	?	-	
SEARCH, Vitamin B9/B12	-	-	-	-	?	-	
NAVIGATOR, valsartan	-	-	-	-	-	-	
Navigator, nateglinide	-	-	-	-	-	-	
ACCORD, fenofibrate, 2010	-	-	-	-	-	-	
ACCORD, BP, 2010	-	-	?	-	-	-	
DIAD	-	-	?	-	-	-	
RECORD	-	-	?	-	-	-	
BARI 2D	-	-	?	-	-	-	
TRANSCEND	-	-	-	-	-	-	
ARISE	-	-	-	-	-	-	
PRoFESS	-	-	-	-	-	-	
WAFACS	?	?	-	-	-	-	
ADVANCE, 2008	-	-	?	-	-	-	
FeAST	-	-	?	-	-	-	
WAVE	-	-	?	-	-	-	

ADVANCE, 2007	-	-	?	-	-	-	
COURAGE	-	-	?	-	-	-	
OAT	-	-	?	-	-	-	
ESPRIT, 2006	-	-	?	-	-	-	
CHARISMA	-	-	-	-	-	-	
RUTH	-	-	-	-	-	-	
4D	-	-	-	-	-	-	
WHS, aspirin	-	-	-	-	-	-	
IDEAL	-	-	?	-	-	-	
WHS, vitamin E	-	-	-	-	-	-	
TNT	-	-	-	-	-	-	
FIELD	-	-	-	-	-	-	
RITA 3	-	-	?	-	-	-	
PROactive	-	-	-	-	-	-	
PROVE IT-TIMI 22, 2005	-	-	-	-	-	-	
HPS, simvastatin	-	-	-	-	-	-	
CARDS	-	-	-	-	-	-	
PROVE IT-TIMI 22, 2004	-	-	-	-	-	-	
PEACE	-	-	-	-	-	-	
ALERT	-	-	-	-	-	-	
EUROPA	?	?	-	-	-	-	
Indo-Mediterranean Diet Heart Study	?	?	?	?	-	-	
PROSPER	-	-	-	-	-	-	
LIPS	-	-	-	-	-	-	
LIFE	-	-	-	-	-	-	
HPS, vitamins, 2002	-	-	?	-	-	-	
HPS, simvastatin, 2002	-	-	?	-	-	-	
LIPID, 2002	-	-	?	-	-	-	
HERS II	-	-	?	?	-	-	
ESPRIT, 2002	-	-	?	-	-	-	
ALLHAT-LLT	-	-	?	?	-	-	
LIPID, 2000	-	-	-	-	-	-	
NORDIL	-	-	?	-	-	-	
ALLHAT	-	-	?	?	-	-	
Rubins et al, 1999	-	-	-	-	-	-	
CAPPP	-	-	?	-	-	-	
LIPID, 1998	-	-	-	-	-	-	
RITA-1	-	-	?	-	-	-	
AFCAPS/TeCAPS	-	-	-	-	-	-	
UKPDS 33	-	-	-	-	-	-	
RITA-2	-	-	?	-	-	-	
CARE	-	-	-	-	-	-	
TRACE	-	-	-	-	-	-	
ASPECT	?	?	-	?	-	-	

4S	-	-	-	-	-	-	-
SOLVD	-	-	-	-	-	-	-
SAVE, 1992	-	-	-	-	-	-	-
SAPAT	?	?	-	-	-	-	-
ETDRS	?	?	?	?	-	-	-
STOP-Hypertension	?	?	-	-	-	-	-
SALT	-	-	?	-	-	-	-
SHEP	-	-	-	-	-	-	-
Smith et al, 1990	-	-	-	-	-	-	-
PHS	-	-	-	-	-	-	-
MDPIT	-	-	-	-	-	-	-
LRC-CPPT	-	-	-	-	-	-	-
Rose et al, 1983	?	?	?	?	-	-	-
Kornitzer et al, 1983	?	?	?	?	-	-	-
BHAT	-	-	-	-	-	-	-
Taylor et al, 1982	-	-	-	-	-	-	-
EPSIM	-	-	?	-	-	-	-
Hjermann et al, 1981	-	-	?	-	-	-	-
AMIS	-	-	-	-	-	-	-
Coronary Drug Project	-	-	-	-	-	-	-
ISCHEMIA	-	-	?	-	-	-	-
BETonMACE	-	-	-	-	-	-	-
VOYAGER PAD	-	-	-	-	-	-	-
ATPCI	-	-	-	-	-	-	-
LoDoCo2	-	-	-	-	-	-	-

Each domain was judged as ‘low risk of bias’ (-), ‘high risk of bias’ (+), or ‘unclear risk of bias’ (?) in each study according to the Revised Cochrane risk-of-bias tool for randomized trials (Sterne, Jonathan A C et al. “RoB 2: a revised tool for assessing risk of bias in randomised trials.” *BMJ (Clinical research ed.)* vol. 366 14898. 28 Aug. 2019, doi:10.1136/bmj.14898)

eTable 3. Trial Abbreviations, Names, and Date of Publication

Trial abbreviation	Trial name	Publication date
-	The Coronary Drug Project ¹⁵	May 1972
AMIS	Aspirin Myocardial Infarction Study ¹⁶	Feb 1980
-	Effect of Diet and Smoking Intervention on the Incidence of Coronary Heart Disease – Oslo Study Group ¹⁷	Dec 1981
EPSIM	Controlled Comparison of Aspirin and Oral Anticoagulants in Prevention of Death after Myocardial Infarction ¹⁸	Sep 1982
-	Long-Term Prevention Study with Oxprenolol in Coronary Heart Disease ¹⁹	Nov 1982
-	Belgian Heart Disease Prevention Project: Incidence and Mortality Results ²⁰	May 1983
-	UK Heart Disease Prevention Project: Incidence and Mortality Results ²¹	May 1983
BHAT	A Randomized Trial of Propranolol in Patient with Acute Myocardial Infarction ²²	Nov 1983
LRC-CPPT	The Lipid Research Clinics Coronary Primary Prevention Trial Results ²³	Jan 1984
MDPIT	The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction ²⁴	Aug 1988
PHS	Final Report on the Aspirin Component of the Ongoing Physicians' Health Study ²⁵	Jul 1989
-	The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction ²⁶	Jul 1990

SHEP	Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons with Isolated Systolic Hypertension ²⁷	Jun 1991
SALT	Swedish Aspirin Low-Dose Trial of 75mg Aspirin as Secondary Prophylaxis after Cerebrovascular Ischemic Events ²⁸	Nov 1991
STOP-Hypertension	Morbidity and Mortality in the Swedish Trial in Old Patients with Hypertension ²⁹	Nov 1991
SAVE	Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction ³⁰	Sep 1992
ETDRS	Aspirin Effects on Mortality and Morbidity in Patients with Diabetes Mellitus ³¹	Sep 1992
SOLVD	Effect of Enalapril on Myocardial Infarction and Unstable Angina in Patient with Low Ejection Fraction ³²	Nov 1992
SAPAT	Double-blind Trial of Aspirin in Primary Prevention of Myocardial Infarction in Patients with Stable Chronic Angina Pectoris ³³	Dec 1992
ASPECT	Effect of Long-term Oral Anticoagulation Treatment on Mortality and Cardiovascular Morbidity after Myocardial Infarction ³⁴	Feb 1994
4S	Randomized Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: the Scandinavian Simvastatin Survival Study ³⁵	Nov 1994
TRACE	A Clinical Trial of the Angiotensin-converting-enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction ³⁶	Dec 1995
CARE	The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels ³⁷	Oct 1996
RITA-2	Coronary Angioplasty versus Medical Therapy for Angina: the Second Randomized Intervention Treatment of Angina ³⁸	Aug 1997

AFCAPS/TexCAPS	Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels ³⁹	May 1998
UKPDS 33	Intensive Blood-glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes ⁴⁰	Sep 1998
RITA-1	Long-term Results of RITA-1 Trial: Clinical and Cost Comparisons of Coronary Angioplasty and Coronary-artery Bypass Grafting ⁴¹	Oct 1998
LIPID	Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels ⁴²	Nov 1998
CAPP	Effect of Angiotensin-converting-enzyme Inhibition Compared with Conventional Therapy on Cardiovascular Morbidity and Mortality in Hypertension ⁴³	Feb 1999
-	Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-density Lipoprotein Cholesterol ⁴⁴	Aug 1999
ALLHAT	Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone ⁴⁵	Apr 2000
NORDIL	Randomized Trial of Effects of Calcium Antagonists Compared with Diuretics and Beta-blockers on Cardiovascular Morbidity and Mortality in Hypertension ⁴⁶	Jul 2000
LIPID	Effects of Pravastatin in 3260 Patients with Unstable Angina ⁴⁷	Dec 2000
LIPID	Long-term Effectiveness and Safety of Pravastatin in 9014 Patients with Coronary Heart Disease and Average Cholesterol Concentrations ⁴⁸	Apr 2002
LIPS	Fluvastatin for Prevention of Cardiac Events following Successful First Percutaneous Coronary Intervention ⁴⁹	Jun 2002
HERS II	Cardiovascular Disease Outcomes during 6.8 Years of Hormone Therapy ⁵⁰	Jul 2002

HPS	MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 High-risk Individuals: a Randomized Placebo-controlled Trial ⁵¹	Jul 2002
HPS	MRC/BHF Heart Protection Study of Antioxidant Vitamin Supplementation in 20,536 High-risk Individuals: a Randomized Placebo-controlled Trial ⁵²	Jul 2002
LIFE	Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients with Isolated Systolic Hypertension and Left Ventricular Hypertrophy ⁵³	Sep 2002
Indo-Mediterranean Diet Heart Study	Effect of an Indo-Mediterranean Diet on Progression of Coronary Artery Disease in High Risk Patients ⁵⁴	Nov 2002
PROSPER	Pravastatin in Elderly Individuals at Risk of Vascular Disease ⁵⁵	Nov 2002
ALLHAT-LLT	Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs. Usual Care ⁵⁶	Dec 2002
ESPRIT	Oestrogen Therapy for Prevention of Reinfarction in Postmenopausal Women ⁵⁷	Dec 2002
ALERT	Effect of Fluvastatin on Cardiac Outcomes in Renal Transplant Recipients ⁵⁸	Jun 2003
EUROPA	Efficacy of Perindopril in Reduction of Cardiovascular Events among Patients with Stable Coronary Artery Disease ⁵⁹	Sep 2003
PROVE IT-TIMI 22	Intensive Versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes ⁶⁰	Apr 2004
CARDS	Primary Prevention of Cardiovascular Disease with Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study ⁶¹	Aug 2004
PEACE	Angiotensin-converting-enzyme Inhibition in Stable Coronary Artery Disease ⁶²	Nov 2004
WHS	A Randomized Trial of Low-dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women ⁶³	Mar 2005

TNT	Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease ⁶⁴	Apr 2005
PROVE IT-TIMI 22	Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome ⁶⁵	Apr 2005
WHS	Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: the Women's Health Study ⁶⁶	Jul 2005
4D	Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis ⁶⁷	Jul 2005
RITA-3	5-year Outcome of an Interventional Strategy in Non-ST-Elevation Acute Coronary Syndrome ⁶⁸	Sep 2005
PROactive	Secondary Prevention of Macrovascular Events in Patients with Type 2 Diabetes in the PROactive Study ⁶⁹	Oct 2005
IDEAL	High-dose Atorvastatin vs Usual-dose Simvastatin for Secondary Prevention after Myocardial Infarction ⁷⁰	Nov 2005
FIELD	Effects of Long-term Fenofibrate Therapy on Cardiovascular Events in 9795 people with Type 2 Diabetes Mellitus ⁷¹	Nov 2005
CHARISMA	Clopidogrel and Aspirin Versus Aspirin Alone for the Prevention of Atherothrombotic Events ⁷²	Apr 2006
ESPRIT	Aspirin Plus Dipyridamole Versus Aspirin Alone after Cerebral Ischemia of Arterial Origin ⁷³	May 2006
RUTH	Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women ⁷⁴	Jul 2006
OAT	Coronary Intervention for Persistent Occlusion after Myocardial Infarction ³	Dec 2006
FeAST	Reduction of Iron Stores and Cardiovascular Outcomes in Patients with Peripheral Arterial Disease ⁷⁵	Feb 2007
COURAGE	Optimal Medical Therapy With or Without PCI for Stable Coronary Disease ²	Apr 2007
WAVE	Oral Anticoagulation and Antiplatelet Therapy and Peripheral Artery Disease ⁷⁶	Jul 2007

ADVANCE	Effects of a Fixed Combination of Perindopril and Indapamide on Macrovascular and Microvascular Outcomes in Patients with Type 2 Diabetes Mellitus ⁷⁷	Sep 2007
WAFACS	Effect of Folic Acid and B Vitamins on Risk of Cardiovascular Events and Total Mortality Among Women at High Risk for Cardiovascular Disease ⁷⁸	May 2008
ARISE	Effects of Succinobucol (AGI-1067) after an Acute Coronary Syndrome ⁷⁹	May 2008
ADVANCE	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes ⁸⁰	Jun 2008
PRoFESS	Aspirin and Extended-release Dipyridamole versus Clopidogrel for Recurrent Stroke ⁸¹	Sep 2008
TRANSCEND	Effect of the Angiotensin-receptor Blocker Telmisartan on Cardiovascular Events in High-risk Patients Intolerant to Angiotensin-converting Enzyme Inhibitors ⁸²	Sep 2008
DIAD	Cardiac Outcomes after Screening for Asymptomatic Coronary Artery Disease in Patients with Type 2 Diabetes ⁸³	Apr 2009
BARI 2D	A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease ⁴	Jun 2009
RECORD	Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes ⁸⁴	Jun 2009
NAVIGATOR	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events ⁸⁵	Apr 2010
NAVIGATOR	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events ⁸⁶	Apr 2010
ACCORD	Effects of Intensive Blood-pressure Control in Type 2 Diabetes ¹⁴	Apr 2010
ACCORD	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus ⁸⁷	Apr 2010
SEARCH	Effects of Homocysteine-lowering with Folic Acid plus Vitamin B12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors ⁸⁸	Jun 2010

SEARCH	Intensive Lowering of LDL Cholesterol with 80mg Versus 20mg Simvastatin Daily in 12,064 Survivors of Myocardial Infarction ⁸⁹	Jun 2010
ACCORD	Long-term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes ⁹⁰	Mar 2011
ROADMAP	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes ⁹¹	Mar 2011
PERFORM	Terutroban versus Aspirin in Patients with Cerebral Ischaemic Events ⁹²	Jun 2011
AIM-HIGH	Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy ⁹³	Dec 2011
PHS II	Multivitamins in the Prevention of Cardiovascular Disease in Men ⁹⁴	Nov 2012
dal-OUTCOMES	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome ⁹⁵	Nov 2012
FREEDOM	Strategies for Multivessel Revascularization in Patients with Diabetes ⁶	Dec 2012
Look AHEAD	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes ⁹⁶	Jul 2013
SAVOR-TIMI 53	Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus ⁹⁷	Oct 2013
AleCardio	Effect of Alogliptin on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients with Type 2 Diabetes Mellitus ⁹⁸	Apr 2014
STABILITY	Darapladib for Preventing Ischemic Events in Stable Coronary Artery Disease ⁹⁹	May 2014
SORT OUT III	Differential Clinical Outcomes after 1 Year Versus 5 Years in a Randomized Comparison of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents ¹⁰⁰	Jun 2014
HPS2-THRIVE	Effects of Extended-release Niacin with Laropiprant in High-risk Patients ¹⁰¹	Jul 2014
SIGNIFY	Ivabradine in Stable Coronary Artery Disease Without Clinical Heart Failure ¹⁰²	Sep 2014

JPPP	Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years or Older with Atherosclerotic Risk Factors ¹⁰³	Dec 2014
PROMISE	Outcomes of Anatomical Versus Functional Testing for Coronary Artery Disease ¹⁰⁴	Apr 2015
CSPPT	Efficacy of Folic Acid Therapy in Primary Prevention of Stroke Among Adults with Hypertension in China ¹⁰⁵	Apr 2015
VADT	Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes ¹⁰⁶	Jun 2015
IMPROVE-IT	Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes ¹⁰⁷	Jun 2015
TECOS	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes ¹⁰⁸	Jul 2015
EMPA-REG OUTCOME	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes ¹⁰⁹	Nov 2015
SPRINT	A Randomized Trial of Intensive Versus Standard Blood-pressure Control ¹¹⁰	Nov 2015
ELIXA	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome ¹¹¹	Dec 2015
EXAMINATION	Clinical Outcomes in Patients with ST-segment Elevation Myocardial Infarction Treated with Everolimus-eluting Stents Versus Bare-metal Stents ¹¹²	Jan 2016
-	Effect of Naltrexone-bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients with Cardiovascular Risk Factors ¹¹³	Mar 2016
IRIS	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack ¹¹⁴	Apr 2016
HOPE-3	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease ¹¹⁵	May 2016
DANAMI 3-DEFER	Deferred Versus Conventional Stent Implantation in Patients with ST-segment Elevation Myocardial Infarction ¹¹⁶	May 2016

SPRINT	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥ 75 Years ¹¹⁷	Jun 2016
LEADER	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes ¹¹⁸	Jul 2016
SAVE	CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea ¹¹⁹	Sep 2016
NORSTENT	Drug-eluting or Bare-metal Stents for Coronary Artery Disease ¹²⁰	Sep 2016
SUSTAIN-6	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes ¹²¹	Nov 2016
CORONARY	Five-year Outcomes after Off-pump or On-pump Coronary-artery Bypass Grafting ¹²²	Dec 2016
FOURIER	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease ¹²³	May 2017
ROOBY-FS	Five-year Outcomes after On-pump and Off-pump Coronary-artery bypass ¹²⁴	Aug 2017
EXSCEL	Effects of Once-weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes ¹²⁵	Sept 2017
CARES	Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout ¹²⁶	Mar 2018
SCOT-HEART	Coronary CT Angiography and 5-year Risk of Myocardial Infarction ¹²⁷	Sep 2018
GLOBAL LEADERS	Ticagrelor Plus Aspirin for 1 Month, Followed by Ticagrelor Monotherapy for 23 Months vs Aspirin Plus Clopidogrel or Ticagrelor for 12 Months, Followed by Aspirin Monotherapy for 12 Months After Implantation of a Drug-eluting Stent ¹²⁸	Sep 2018
ARRIVE	Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease ¹²⁹	Sep 2018
ASCEND	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus ¹³⁰	Oct 2018
ASCEND	Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus ¹³¹	Oct 2018

ASPREE	Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly ¹³²	Oct 2018
ODYSSEY OUTCOMES	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome ¹³³	Nov 2018
CARMELINA	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk ¹³⁴	Jan 2019
REDUCE-IT	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia ¹³⁵	Jan 2019
VITAL	Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer ¹³⁶	Jan 2019
VITAL	Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease ¹³⁷	Jan 2019
REGROUP	Randomized Trial of Endoscopic or Open Vein-graft Harvesting for Coronary-artery Bypass ¹³⁸	Jan 2019
DECLARE-TIMI 58	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes ¹³⁹	Jan 2019
PIVOTAL	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis ¹⁴⁰	Jan 2019
CIRT	Low-dose Methotrexate for the Prevention of Atherosclerotic Events ¹⁴¹	Feb 2019
REWIND	Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes ¹⁴²	July 2019
PolyIran	Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases ¹⁴³	Aug 2019
AFIRE	Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease ¹⁴⁴	Sep 2019
THEMIS	Ticagrelor in Patients with Stable Coronary Disease and Diabetes ¹⁴⁵	Oct 2019
COMPLETE	Complete Revascularization with Multivessel PCI for Myocardial Infarction ¹⁴⁶	Oct 2019
EXCEL	Five-year Outcomes after PCI or CABG for Left Main Coronary Disease ¹⁰	Nov 2019

-	A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke ¹⁴⁷	Jan 2020
ISCHEMIA	Initial Invasive or Conservative Strategy for Stable Coronary Disease ¹¹	Apr 2020
BETonMACE	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes ¹⁴⁸	Apr 2020
VOYAGER PAD	Rivaroxaban in Peripheral Artery Disease after Revascularization ¹⁴⁹	May 2020
ATPCI	Efficacy and Safety of Trimetazidine after Percutaneous Coronary Intervention ¹⁵⁰	Sept 2020
LoDoCo2	Colchicine in Patients with Chronic Coronary Disease ¹⁵¹	Nov 2020

eReferences

1. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. *Circulation*. 1979;59(3):607-609.
2. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007;356(15):1503-1516.
3. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med*. 2006;355(23):2395-2407.
4. Group BDS, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med*. 2009;360(24):2503-2515.
5. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. *Circulation*. 2007;116(22):2634-2653.
6. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med*. 2012;367(25):2375-2384.
7. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). *J Am Coll Cardiol*. 2001;38(7):2114-2130.
8. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. *EuroIntervention*. 2010;5(7):871-874.
9. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *J Am Coll Cardiol*. 2012;60(16):1581-1598.
10. Stone GW, Kappetein AP, Sabik JF, et al. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. *N Engl J Med*. 2019;381(19):1820-1830.
11. Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med*. 2020;382(15):1395-1407.
12. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol*. 2000;36(3):959-969.
13. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation*. 2003;108(20):2543-2549.
14. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358(24):2545-2559.
15. The Coronary Drug Project: Findings Leading to Further Modifications of Its Protocol With Respect to Dextrothyroxine. *JAMA*. 1972;220(7):996-1008.
16. A Randomized, Controlled Trial of Aspirin in Persons Recovered From Myocardial Infarction. *JAMA*. 1980;243(7):661-669.

17. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. *Lancet*. 1981;2(8259):1303-1310.
18. A Controlled Comparison of Aspirin and Oral Anticoagulants in Prevention of Death after Myocardial Infarction. *New England Journal of Medicine*. 1982;307(12):701-708.
19. Taylor SH, Silke B, Ebbutt A, Sutton GC, Prout BJ, Burley DM. A Long-Term Prevention Study with Oxprenolol in Coronary Heart Disease. *New England Journal of Medicine*. 1982;307(21):1293-1301.
20. Kornitzer M, Dramaix M, Thilly C, et al. BELGIAN HEART DISEASE PREVENTION PROJECT: INCIDENCE AND MORTALITY RESULTS. *The Lancet*. 1983;321(8333):1066-1070.
21. Rose G, Tunstall-Pedoe HD, Heller RF. UK HEART DISEASE PREVENTION PROJECT: INCIDENCE AND MORTALITY RESULTS. *The Lancet*. 1983;321(8333):1062-1066.
22. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. *Jama*. 1983;250(20):2814-2819.
23. The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease. *JAMA*. 1984;251(3):351-364.
24. The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction. *New England Journal of Medicine*. 1988;319(7):385-392.
25. Final report on the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med*. 1989;321(3):129-135.
26. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. *N Engl J Med*. 1990;323(3):147-152.
27. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. *Jama*. 1991;265(24):3255-3264.
28. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. *Lancet*. 1991;338(8779):1345-1349.
29. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekblom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet*. 1991;338(8778):1281-1285.
30. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med*. 1992;327(10):669-677.
31. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. *Jama*. 1992;268(10):1292-1300.
32. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. *Lancet*. 1992;340(8829):1173-1178.
33. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. *Lancet*. 1992;340(8833):1421-1425.
34. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. *Lancet*. 1994;343(8896):499-503.
35. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344(8934):1383-1389.

36. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med*. 1995;333(25):1670-1676.
37. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med*. 1996;335(14):1001-1009.
38. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet*. 1997;350(9076):461-468.
39. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *Jama*. 1998;279(20):1615-1622.
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet*. 1998;352(9131):837-853.
41. Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. *Lancet*. 1998;352(9138):1419-1425.
42. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med*. 1998;339(19):1349-1357.
43. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet*. 1999;353(9153):611-616.
44. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med*. 1999;341(6):410-418.
45. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. *Jama*. 2000;283(15):1967-1975.
46. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*. 2000;356(9227):359-365.
47. Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. *Lancet*. 2000;356(9245):1871-1875.
48. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. *Lancet*. 2002;359(9315):1379-1387.
49. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *Jama*. 2002;287(24):3215-3222.
50. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *Jama*. 2002;288(1):49-57.
51. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360(9326):7-22.
52. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360(9326):23-33.

53. Kjeldsen SE, Dahlöf B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *Jama*. 2002;288(12):1491-1498.
54. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. *Lancet*. 2002;360(9344):1455-1461.
55. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002;360(9346):1623-1630.
56. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *Jama*. 2002;288(23):2998-3007.
57. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. *Lancet*. 2002;360(9350):2001-2008.
58. Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet*. 2003;361(9374):2024-2031.
59. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003;362(9386):782-788.
60. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*. 2004;350(15):1495-1504.
61. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*. 2004;364(9435):685-696.
62. Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. *New England Journal of Medicine*. 2004;351(20):2058-2068.
63. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*. 2005;352(13):1293-1304.
64. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*. 2005;352(14):1425-1435.
65. Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. *N Engl J Med*. 2005;352(16):1646-1654.
66. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. *Jama*. 2005;294(1):56-65.
67. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med*. 2005;353(3):238-248.
68. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. *Lancet*. 2005;366(9489):914-920.
69. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet*. 2005;366(9493):1279-1289.
70. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *Jama*. 2005;294(19):2437-2445.

71. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005;366(9500):1849-1861.
72. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354(16):1706-1717.
73. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet*. 2006;367(9523):1665-1673.
74. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *N Engl J Med*. 2006;355(2):125-137.
75. Zacharski LR, Chow BK, Howes PS, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. *Jama*. 2007;297(6):603-610.
76. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. *N Engl J Med*. 2007;357(3):217-227.
77. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007;370(9590):829-840.
78. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. *Jama*. 2008;299(17):2027-2036.
79. Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;371(9626):1761-1768.
80. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358(24):2560-2572.
81. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med*. 2008;359(12):1238-1251.
82. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. *Lancet*. 2008;372(9644):1174-1183.
83. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *Jama*. 2009;301(15):1547-1555.
84. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet*. 2009;373(9681):2125-2135.
85. Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med*. 2010;362(16):1463-1476.
86. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med*. 2010;362(16):1477-1490.
87. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362(17):1563-1574.
88. Armitage JM, Bowman L, Clarke RJ, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. *Jama*. 2010;303(24):2486-2494.

89. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet*. 2010;376(9753):1658-1669.
90. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med*. 2011;364(9):818-828.
91. Haller H, Ito S, Izzo JL, Jr., et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *N Engl J Med*. 2011;364(10):907-917.
92. Bousser MG, Amarenco P, Chamorro A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. *Lancet*. 2011;377(9782):2013-2022.
93. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365(24):2255-2267.
94. Sesso HD, Christen WG, Bubes V, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *Jama*. 2012;308(17):1751-1760.
95. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med*. 2012;367(22):2089-2099.
96. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med*. 2013;369(2):145-154.
97. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317-1326.
98. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of alogliptin on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. *Jama*. 2014;311(15):1515-1525.
99. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med*. 2014;370(18):1702-1711.
100. Maeng M, Tilsted HH, Jensen LO, et al. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. *Lancet*. 2014;383(9934):2047-2056.
101. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med*. 2014;371(3):203-212.
102. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. *N Engl J Med*. 2014;371(12):1091-1099.
103. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. *Jama*. 2014;312(23):2510-2520.
104. Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372(14):1291-1300.
105. Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. *Jama*. 2015;313(13):1325-1335.
106. Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;372(23):2197-2206.
107. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med*. 2015;372(25):2387-2397.
108. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2015;373(3):232-242.

109. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015;373(22):2117-2128.
110. Wright JT, Jr., Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015;373(22):2103-2116.
111. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. *N Engl J Med*. 2015;373(23):2247-2257.
112. Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. *Lancet*. 2016;387(10016):357-366.
113. Nissen SE, Wolski KE, Prcela L, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. *Jama*. 2016;315(10):990-1004.
114. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. *N Engl J Med*. 2016;374(14):1321-1331.
115. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med*. 2016;374(21):2021-2031.
116. Kelbæk H, Høfsten DE, Køber L, et al. Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. *Lancet*. 2016;387(10034):2199-2206.
117. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥ 75 Years: A Randomized Clinical Trial. *Jama*. 2016;315(24):2673-2682.
118. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):311-322.
119. McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N Engl J Med*. 2016;375(10):919-931.
120. Bønaa KH, Mannsverk J, Wiseth R, et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. *N Engl J Med*. 2016;375(13):1242-1252.
121. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016;375(19):1834-1844.
122. Lamy A, Devereaux PJ, Prabhakaran D, et al. Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. *N Engl J Med*. 2016;375(24):2359-2368.
123. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med*. 2017;376(18):1713-1722.
124. Shroyer AL, Hattler B, Wagner TH, et al. Five-Year Outcomes after On-Pump and Off-Pump Coronary-Artery Bypass. *N Engl J Med*. 2017;377(7):623-632.
125. Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017;377(13):1228-1239.
126. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. *N Engl J Med*. 2018;378(13):1200-1210.
127. Newby DE, Adamson PD, Berry C, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. *N Engl J Med*. 2018;379(10):924-933.
128. Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet*. 2018;392(10151):940-949.

129. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2018;392(10152):1036-1046.
130. Bowman L, Mafham M, Wallendszus K, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. *N Engl J Med*. 2018;379(16):1529-1539.
131. Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. *N Engl J Med*. 2018;379(16):1540-1550.
132. McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. *N Engl J Med*. 2018;379(16):1509-1518.
133. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med*. 2018;379(22):2097-2107.
134. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. *Jama*. 2019;321(1):69-79.
135. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med*. 2019;380(1):11-22.
136. Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. *N Engl J Med*. 2019;380(1):23-32.
137. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. *N Engl J Med*. 2019;380(1):33-44.
138. Zenati MA, Bhatt DL, Bakaeen FG, et al. Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass. *N Engl J Med*. 2019;380(2):132-141.
139. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2019;380(4):347-357.
140. Macdougall IC, White C, Anker SD, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. *N Engl J Med*. 2019;380(5):447-458.
141. Ridker PM, Everett BM, Pradhan A, et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. *N Engl J Med*. 2019;380(8):752-762.
142. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394(10193):121-130.
143. Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. *Lancet*. 2019;394(10199):672-683.
144. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. *N Engl J Med*. 2019;381(12):1103-1113.
145. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. *N Engl J Med*. 2019;381(14):1309-1320.
146. Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. *N Engl J Med*. 2019;381(15):1411-1421.
147. Amarenco P, Kim JS, Labreuche J, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N Engl J Med*. 2020;382(1):9.
148. Ray KK, Nicholls SJ, Buhr KA, et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. *Jama*. 2020;323(16):1565-1573.
149. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. *New England Journal of Medicine*. 2020;382(21):1994-2004.

150. Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;396(10254):830-838.
151. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. *N Engl J Med*. 2020;383(19):1838-1847.